A practical reference on 肽纯度: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-24. Anything still debated is marked as such rather than presented as settled.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Material sold for laboratory use varies widely in stated purity and documentation. A certificate of analysis should list the analytical method, the column and detector used, and the observed purity value. Independent verification by an outside laboratory is the practical way to confirm identity when documentation is absent or internally inconsistent. Regulatory status differs by country, and a product legal in one jurisdiction may be unapproved or controlled in another.
Identity and purity of semax are established with reversed-phase high-performance liquid chromatography coupled to ultraviolet detection, usually at 214 nanometres. Mass spectrometry, most often electrospray ionisation in positive mode, confirms the molecular mass and reveals truncated sequences. Amino acid analysis and peptide mapping after enzymatic digestion provide additional structural confirmation. Laboratories typically report purity as the percentage area of the main peak, a figure that does not capture isomeric or oxidised variants unless the method resolves them.
The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide (ACTH fragment analog) | Not a steroid; does not belong to the melanocortin agonist drugs by marketing category |
| Molecular formula | C37H51N9O10S (commonly cited) | Reported values vary slightly with salt and counter-ion content |
| Appearance | White to off-white lyophilized powder | A single batch may appear as a loose cake or fluffy solid |
| Solubility | Freely soluble in water and aqueous buffer | Stock solutions are usually prepared in sterile water or saline |
| Typical storage | −20 °C or below, desiccated and protected from light | Seal opened vials promptly to limit moisture uptake |
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
稳定性主要由水解与氧化两条路径支配。肽键在中性或弱酸性条件下相对稳定，遇到强碱或长时间高温则明显断裂；甲硫氨酸侧链容易被氧化成亚砜，使主峰前移并拉低实际含量。金属离子、光照和反复冻融会进一步促进降解或聚集。冻干粉在低温避光条件下可存放较长时间，配制后的水溶液通常需要冷藏并尽快用完。
纯度评估以反相高效液相色谱为主，通过主峰面积百分比给出粗略结果，再配合电喷雾质谱核对分子量。氨基酸分析可验证组成比例，手性色谱或毛细管电泳用于检查残基构型。常见杂质包括缺失序列的短肽、氧化产物与二聚体。由于多数市售品不附带完整检验报告，独立第三方检测常被用来核实标称值。
Carboxypeptidase E (CPE), also known as carboxypeptidase H (CPH) and enkephalin convertase, is an enzyme that in humans is encoded by the CPE gene. This enzyme catalyzes the release of C-terminal arginine or lysine residues from polypeptides. CPE is involved in the biosynthesis of most neuropeptides and peptide hormones. The production of neuropeptides and peptide hormones typically requires two sets of enzymes that cleave the peptide precursors, which are small proteins. First, proprotein convertases cut the precursor at specific sites to generate intermediates containing C-terminal basic residues (lysine and/or arginine). These intermediates are then cleaved by CPE to remove the basic residues. For some peptides, additional processing steps, such as C-terminal amidation, are subsequently required to generate the bioactive peptide, although for many peptides the action of the proprotein convertases and CPE is sufficient to produce the bioactive peptide.
The reaction interconverts the nucleotide, guanosine monophosphate (GMP) and guanosine diphosphate (GDP) by transferring a phosphate group from the cofactor, adenosine triphosphate (ATP), which is converted to adenosine diphosphate (ADP). The enzyme has very widespread occurrence, for example in L cells, Escherichia coli, rat liver, and calf thymus. Guanylate kinase is essential for recycling GMP and indirectly, cGMP. In prokaryotes (such as Escherichia coli), lower eukaryotes (such as yeast) and in vertebrates, it is a highly conserved monomeric protein of about 200 amino acids which has been shown to be structurally similar to protein A57R (or SalG2R) from various strains of Vaccinia virus. Systems biology analyses carried out by the team of Andreas Dräger also identified a pivotal role of this enzyme in the replication of SARS-CoV-2 within the human airways.
Gram staining is used to determine gram status to classifying bacteria broadly based on the composition of their cell wall. Gram staining uses crystal violet to stain cell walls, iodine (as a mordant), and a fuchsin or safranin counterstain to (mark all bacteria). Gram status, helps divide specimens of bacteria into two groups, generally representative of their underlying phylogeny. This characteristic, in combination with other techniques makes it a useful tool in clinical microbiology laboratories, where it can be important in early selection of appropriate antibiotics. On most Gram-stained preparations, Gram-negative organisms appear red or pink due to their counterstain. Due to the presence of higher lipid content, after alcohol-treatment, the porosity of the cell wall increases, hence the CVI complex (crystal violet – iodine) can pass through. Thus, the primary stain is not retained. In addition, in contrast to most Gram-positive bacteria, Gram-negative bacteria have only a few layers of peptidoglycan and a secondary cell membrane made primarily of lipopolysaccharide.
Hoarseness, where the child makes moves to moan, but emits no sound or just faint moans caused by nerve paralysis Weight loss, becoming thinner and then marasmic as the disease progresses Vomiting Diarrhea Pale skin Edema Ill temper Alterations of the cardiovascular system, especially tachycardia (rapid heart rate) Convulsions occasionally observed in the terminal stages
(2005), philanthropist, investor, activist, son of John Kluge '37 Alana Mayo (2006), president of Orion Pictures Liesel Pritzker Simmons (2006), former child actress, A Little Princess; granddaughter of businessman Abram Nicholas Pritzker, heiress to the Hyatt hotels fortune, philanthropist Wayne Ting (2006), CEO of Lime Marco Zappacosta (2007), co-founder and CEO of Thumbtack, son of Logitech founder Pierluigi Zappacosta Adam Pritzker (2008), co-founder of General Assembly, grandson of Jay Pritzker and member of the Pritzker family Jared Hecht (2009), co-founder of GroupMe Ariana Rockefeller (2009), fashion designer and great-great-granddaughter of John D. Rockefeller Zach Sims* (2012), co-founder of Codecademy Beverly Leon (2014), former midfielder of Sunderland A.F.C. Ladies, CEO of Local Civics Nicole LaPointe Jameson (2016), CEO of Evil Geniuses Korawad Chearavanont* (2017), Thai internet entrepreneur and grandson of Dhanin Chearavanont
Sources: en.wikipedia.org
== Limitations == The cytocentrifugation process can cause cells to appear distorted. Cells located at the centre of the smear may look compressed compared to cells at the periphery. Cell nuclei may develop artifactual clefts, lobes, or holes, and the cytoplasm may appear vacuolated or develop irregular projections. Cytoplasmic granules may be pushed to the periphery of the cell. If the cell count is high, cells may be distorted due to crowding; therefore, samples with high cell counts are diluted prior to smear preparation.
=== Definition === The term "opioid" originated in the 1950s. It combines "opium" + "-oid" meaning "opiate-like" ("opiates" being morphine and similar drugs derived from opium). The first scientific publication to use it, in 1963, included a footnote stating, "In this paper, the term, 'opioid', is used in the sense originally proposed by George H. Acheson (personal communication) to refer to any chemical compound with morphine-like activities". By the late 1960s, research found that opiate effects are mediated by activation of specific molecular receptors in the nervous system, which were termed "opioid receptors". The definition of "opioid" was later refined to refer to substances that have morphine-like activities that are mediated by the activation of opioid receptors. One modern pharmacology textbook states: "the term opioid applies to all agonists and antagonists with morphine-like activity, and also the naturally occurring and synthetic opioid peptides". Another pharmacology reference eliminates the morphine-like requirement: "Opioid, a more modern term, is used to designate all substances, both natural and synthetic, that bind to opioid receptors (including antagonists)". Some sources define the term opioid to exclude opiates, and others use opiate comprehensively instead of opioid, but opioid used inclusively is considered modern, preferred and is in wide use.
== Available forms == κ-Bungarotoxin naturally occurs in Bungarus multicinctus venom glands[11]. The polypeptide consists of 66 amino acids and is cross-linked by five disulfide bonds. This is similar to LS-III, a venom purified from Laticauda semifasciata[12]. κ-Bungarotoxin can form heterodimers, thereby creating κ-2-Bungarotoxin and κ-3-Bungarotoxin. These differences are also observed globally. Though both κ-2- and κ-3-bungarotoxin are derived from Bungarus multicinctus venom, these are prevalent in the province of Guangdong, China, whereas κ-bungarotoxin is found in the Taiwanese B. multicinctus. These forms might have an evolutionary advantage in each specific region. Another form of κ-bungarotoxin is the α-bungarotoxin. κ-Bungarotoxin exhibits a 47% structural homology to α-bungarotoxin, but has an even shorter COOH-terminal than LS-III. α-Bungarotoxin also consists of the amino acid tryptanophyl, which is not present in κ-bungarotoxin. α-Bungarotoxin binds with a 200 times stronger affinity to nicotinic receptors than κ-bungarotoxin. Lastly, β-bungarotoxin also resembles the bungarotoxin family. β-Bungarotoxin is a potent inhibitor of the transport system for choline on the presynaptic terminal. It differs in the fact that β-bungarotoxin does not bind to a receptor, but binds enzymatically. β-Bungarotoxin will bind to voltage-gated potassium channels, after which phospholipase A2-mediated destruction of membrane phospholipids occurs in the nerves.
Chemical modification of wood. Wood and Fiber Sci., 26(2):270-280. Langrish, T.A.G. and Walker, J.C.F. (1993). Transport Processes in Wood. In: Walker, J.C.F. Primary Wood Processing. Chapman and Hall, London. pp121–152. Panshin, A.J. and de Zeeuw, C. (1970). Textbook of Wood Technology. Volume 1, Third Edition. McGraw-Hill, New York, 705 p. Pordage, L.J. and Langrish, T.A.G. (1999). Simulation of the effect of air velocity in the drying of hardwood timber. Drying Technology - An International Journal, 17(1&2):237-256. Rasmussen, E.F. (1988). Forest Products Laboratory, U.S. Department of Agriculture. (ed.). Dry Kiln Operators Manual. Hardwood Research Council. Rowell, R.M. (1983). Chemical modification of wood. Forest Product Abstract, 6(12):363-382. Rowell, R.M. (1991). Chemical Modification of Wood. In: Hon, D.N.-S and Shiraishi, N. (eds), Wood and Cellulosic Chemistry. pp. 703–756. Marcel Dekker, Inc., New York. Siau, J.F. (1984). Transport processes in wood. Springer-Verlag, New York. 245p. Sjostrom, E. (1993). Wood Chemistry: Fundamentals and Applications. Academic Press Limited, London. 293p. Skaar, C. (1988). Wood Water Relations. Springer-Verlag, New York. 283p. Stamm, A. J. (1964). Wood and Cellulose Science. Ronald Press, New York. 509p. Standard Australia (2000). Timber - Classification into Strength Groups. Australian/New Zealand Standard (AS/NZS) 2878. Sydney. 36p. Standard Australia (2001). Timber - Assessment of Drying Quality. Australian/New Zealand Standard (AS/NZS) 4787. Sydney. 24p. Strumillo, C. and Kudra, T. (1986).
Sources: en.wikipedia.org
=== Corporate affairs === In December 2025, Enhanced Games CEO and co-founder Maximilian Martin stated that the venture was not intended to compete directly with the Olympic movement; he characterized the two models as serving distinct purposes, asserting that the event would pursue organizational goals independent of the Olympic Games. The Enhanced Games announced a merger agreement in 2026 with a firm named "A Paradise Acquisition" with a projected valuation of $1.2 billion, for the purpose of listing on the New York Stock Exchange. Preceding the inaugural 2026 games, the entity went public in May 2026.
== Degradation mechanism == PLGA degradation is mainly governed by bulk erosion rather than surface erosion, specifically in microspheres and implants. Water penetration throughout the polymer matrix in these systems results in homogeneous hydrolysis of its ester linkages, leading to a progressive decrease in molecular weight before significant loss of mass occurs. It has been shown that the time required for degradation of PLGA is related to the monomers' ratio used in production: the higher the content of glycolide units, the lower the time required for degradation as compared to predominantly lactide materials. An exception to this rule is the copolymer with 50:50 monomers' ratio which exhibits the faster degradation (about two months). In addition, polymers that are end-capped with esters (as opposed to the free carboxylic acid) demonstrate longer degradation half-lives. This flexibility in degradation has made it convenient for fabrication of many medical devices, such as, grafts, sutures, implants, prosthetic devices, surgical sealant films, micro and nanoparticles. Degradation behavior is also influenced by factors like polymer composition, molecular weight, pH, ionic strength, etc. This process is usually accompanied by the formation of an acidic environment within the polymer matrix due to the accumulation of lactic and glycolic acid degradation products, which can further accelerate autocatalytic degradation. Limited diffusion of acidic byproducts can lead to localized pH gradients and heterogeneous degradation within larger PLGA systems.
=== Education === Thomson's early education was in small private schools where he demonstrated outstanding talent and interest in science. In 1870, he was admitted to Owens College in Manchester (now the University of Manchester) at the unusually young age of 14, and came under the influence of Balfour Stewart, Professor of Physics, who initiated him into physical research. He began experimenting with contact electrification and soon published his first scientific paper. His parents planned to enroll him as an apprentice engineer to Sharp, Stewart & Co, a locomotive manufacturer, but these plans were cut short when his father died in 1873. In 1876, Thomson moved on to Trinity College, Cambridge. In 1880, he received his B.A. in mathematics (Second Wrangler in the Tripos and 2nd Smith's Prizeman). He applied for and became a Fellow of Trinity College the following year. He obtained an M.A. (Adams Prizeman) in 1883.
Sources: en.wikipedia.org
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.
It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.
It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.
Reversed-phase high-performance liquid chromatography is the standard method, with detection in the ultraviolet range. Peak area percentage yields a purity figure for the main component. Mass spectrometry is normally run alongside to confirm molecular identity.